Hemophilia Federation of America is a national nonprofit organization that assists, educates, and advocates for the bleeding disorders community.
Note: The below is an edited press release from Alnylam Pharmaceuticals, Inc. The original release can be read in its entirety here. Alnylam Pharmaceuticals, Inc. announced on Monday, March 14, 2016, that it has initiated dosing of hemophilia patients with inhibitors in Part D of an ongoing Phase 1 clinical trial evaluating a once-monthly subcutaneous dose […]
Sign up for E-mails, Dateline Magazine, and other ways to stay connected.